OKYO Pharma Ltd. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its innovative drug, urcosimod, for the treatment of neuropathic corneal pain (NCP). This designation is intended to expedite the development and review process for therapies addressing serious conditions with unmet medical needs. Neuropathic corneal pain is a debilitating condition characterized by severe eye pain due to nerve damage, affecting patients worldwide. OKYO Pharma is committed to advancing urcosimod through clinical development and regulatory review to provide an effective treatment option for this condition. The Fast Track designation allows for more frequent meetings with the FDA, eligibility for Accelerated Approval and Priority Review, and potential Rolling Review of the New Drug Application, which could significantly accelerate the availability of urcosimod to patients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.